# Genome Editing * **Definition:** A set of technologies that enable precise modifications to an organism's DNA, allowing for specific changes to achieve desired traits or outcomes, often used in healthcare for developing therapies for genetic diseases. * **Taxonomy:** Healthcare Topics / Genome Editing ## News * Selected news on the topic of **Genome Editing**, for healthcare technology leaders * 4.6K news items are in the system for this topic * Posts have been filtered for tech and healthcare-related keywords | Date | Title | Source | | --- | --- | --- | | 5/27/2025 | [**Gene editing leaders call for 10-year suspension of heritable human genome editing**](https://www.fiercebiotech.com/research/gene-editing-leaders-call-10-year-suspension-heritable-human-genome-editing) | [[FierceBiotech]] | | 5/9/2025 | [**Precision Medicine Market Analysis Report 2024-2030: Bristol-Myers Squibb, Illumina ...**](https://finance.yahoo.com/news/precision-medicine-market-analysis-report-131300143.html) | [[Yahoo Finance]] | | 4/7/2025 | [**SOHM, Inc. Launches New AI Team to Advance ABBIE System and Genome Editing Innovations**](https://finance.yahoo.com/news/sohm-inc-launches-ai-team-133000799.html) | [[Yahoo Finance]] | | 3/30/2025 | [**Genome Editing Market Trends: Precision Medicine and Therapeutic Breakthroughs**](http://prsync.com/maximize-market-research/genome-editing-market-trends-precision-medicine-and-therapeutic-breakthroughs-4696791/) | [[PRSync]] | | 3/7/2025 | [**The Future of Biotechnology: Medical, Food Technology, and Bioinformatics Innovations**](https://medium.com/@sourabh.more_60784/the-future-of-biotechnology-medical-food-technology-and-bioinformatics-innovations-37c067197fbb) | [[Medium]] | | 3/6/2025 | [**Global Genome Editing Market to Grow Rapidly at a CAGR ~13y 2032 - DelveInsight**](https://www.globenewswire.com/news-release/2025/03/06/3038530/0/en/Global-Genome-Editing-Market-to-Grow-Rapidly-at-a-CAGR-13-by-2032-DelveInsight.html) | [[Globe Newswire]] | | 3/6/2025 | [**Global Genome Editing Market to Grow Rapidly at a CAGR ~13y 2032 - DelveInsight**](https://finance.yahoo.com/news/global-genome-editing-market-grow-180000179.html) | [[Yahoo Finance]] | | 12/31/2024 | [**Precision Medicine Software Market Focused Insights 2024-2029, with Key Player Profiles of ...**](https://www.businesswire.com/news/home/20241231013633/en/Precision-Medicine-Software-Market-Focused-Insights-2024-2029-with-Key-Player-Profiles-of-Syapse-AccessDX-Laboratory-Fabric-Genomics-Foundation-Medicine-Intel-and-IBM---ResearchAndMarkets.com) | [[Business Wire]] | | 12/31/2024 | [**Precision Medicine Software Market Focused Insights 2024-2029, with Key Player Profiles of Syapse, AccessDX Laboratory, Fabric Genomics, Foundation Medicine, Intel and IBM - ResearchAndMarkets.com**](http://www.businesswire.com/news/home/20241231013633/en/Precision-Medicine-Software-Market-Focused-Insights-2024-2029-with-Key-Player-Profiles-of-Syapse-AccessDX-Laboratory-Fabric-Genomics-Foundation-Medicine-Intel-and-IBM---ResearchAndMarkets.com/?feedref=JjAwJuNHiystnCoBq_hl-Q-tiwWZwkcswR1UZtV7eGe24xL9TZOyQUMS3J72mJlQ7fxFuNFTHSunhvli30RlBNXya2izy9YOgHlBiZQk2LOzmn6JePCpHPCiYGaEx4DL1Rq8pNwkf3AarimpDzQGuQ==) | [[Business Wire]] | | 12/31/2024 | [**Precision Medicine Software Market Focused Insights 2024-2029, with Key Player Profiles of Syapse, AccessDX Laboratory, Fabric Genomics, Foundation Medicine, Intel and IBM - ResearchAndMarkets.com**](http://www.businesswire.com/news/home/20241231013633/en/Precision-Medicine-Software-Market-Focused-Insights-2024-2029-with-Key-Player-Profiles-of-Syapse-AccessDX-Laboratory-Fabric-Genomics-Foundation-Medicine-Intel-and-IBM---ResearchAndMarkets.com/?feedref=JjAwJuNHiystnCoBq_hl-RLXHJgazfQJNuOVHefdHP-D8R-QU5o2AvY8bhI9uvWSD8DYIYv4TIC1g1u0AKcacnnViVjtb72bOP4-4nHK5ieT3WxPE8m_kWI77F87CseT) | [[Business Wire]] | | 12/9/2024 | [**Synthetic Biology Focused Insights Report 2024-2029 with Competitive Analysis of 38 Vendors - Agilent, Codexis, Eurofins Scientific, Illumina, Novozymes, and Thermo Fisher Scientific Lead - ResearchAndMarkets.com**](http://www.businesswire.com/news/home/20241209196246/en/Synthetic-Biology-Focused-Insights-Report-2024-2029-with-Competitive-Analysis-of-38-Vendors---Agilent-Codexis-Eurofins-Scientific-Illumina-Novozymes-and-Thermo-Fisher-Scientific-Lead---ResearchAndMarkets.com/?feedref=JjAwJuNHiystnCoBq_hl-RLXHJgazfQJNuOVHefdHP-D8R-QU5o2AvY8bhI9uvWSD8DYIYv4TIC1g1u0AKcacnnViVjtb72bOP4-4nHK5ieT3WxPE8m_kWI77F87CseT) | [[Business Wire]] | | 12/4/2024 | [**South Africa's new research guidelines are not a green light for heritable human genome editing**](https://theconversation.com/south-africas-new-research-guidelines-are-not-a-green-light-for-heritable-human-genome-editing-243552) | [[The Conversation]] | | 12/4/2024 | [**South Africa's new research guidelines are not a green light for heritable human genome editing**](https://medicalxpress.com/news/2024-12-south-africa-guidelines-green-heritable.html) | [[MedicalXpress]] | | 11/25/2024 | [**Digi-Tech Pharma & AI Conference 2025: AI and Genomics Take Center Stage (London ...**](https://www.marketwatch.com/press-release/digi-tech-pharma-ai-conference-2025-ai-and-genomics-take-center-stage-london-united-kingdom-may-28-29-2025-researchandmarkets-com-2a20b074) | [[MarketWatch]] | | 11/22/2024 | [**Genome Editing Market Size Projected to Reach USD 32.72 Billion by 2032, Driven by ...**](https://finance.yahoo.com/news/genome-editing-market-size-projected-140000347.html) | [[Yahoo Finance]] | | 11/7/2024 | [**Will South Africa become first country to accept controversial form of human genome editing?**](https://www.nature.com/articles/d41586-024-03643-4) | [[Nature]] | | 10/31/2024 | [**Genome Editing / Genome Engineering Strategic Research Report 2024: Global Market to Reach $37.2 Billion by 2030 - Advances in CRISPR Technology Revolutionize Genome Editing Applications - ResearchAndMarkets.com**](http://www.businesswire.com/news/home/20241031247940/en/Genome-Editing-Genome-Engineering-Strategic-Research-Report-2024-Global-Market-to-Reach-37.2-Billion-by-2030---Advances-in-CRISPR-Technology-Revolutionize-Genome-Editing-Applications---ResearchAndMarkets.com/?feedref=JjAwJuNHiystnCoBq_hl-RLXHJgazfQJNuOVHefdHP-D8R-QU5o2AvY8bhI9uvWSD8DYIYv4TIC1g1u0AKcacnnViVjtb72bOP4-4nHK5ieT3WxPE8m_kWI77F87CseT) | [[Business Wire]] | | 10/26/2024 | [**South Africa has amended its research guidelines to allow for heritable human genome editing**](https://medicalxpress.com/news/2024-10-south-africa-amended-guidelines-heritable.html) | [[MedicalXpress]] | | 10/21/2024 | [**HuidaGene Therapeutics Appoints TJ Cradick, PhD as Chief Technology Officer to Lead ...**](https://www.prnewswire.com/news-releases/huidagene-therapeutics-appoints-tj-cradick-phd-as-chief-technology-officer-to-lead-delivery-science-and-genome-editing-innovations-302281537.html) | [[PR Newswire]] | | 9/23/2024 | [**Compact 'gene scissors' enable effective genome editing, may offer future treatment of high ...**](https://phys.org/news/2024-09-compact-gene-scissors-enable-effective.html) | [[Phys Org]] | | 9/13/2024 | [**Genome Editing/Genome Engineering Market Key Drivers, Analysis, Trends, Overview, and ...**](https://www.whatech.com/og/markets-research/medical/880684-genome-editing-genome-engineering-market-key-drivers-analysis-trends-overview-and-forecast-to-2033.html) | whatech.com | | 7/21/2024 | [**Synthetic Biology Market Size, Share, Growth, and Forecast 2023-2032 - WhaTech**](https://www.whatech.com/og/markets-research/medical/859265-synthetic-biology-market-size-share-growth-and-forecast-2023-2032) | whatech.com | | 7/17/2024 | [**Harvard Business School Announces Its 2024-2025 Blavatnik Fellows - News**](https://www.hbs.edu/news/releases/Pages/2024-2025-blavatnik-fellows.aspx) | hbs.edu | | 7/2/2024 | [**Top 10 CRISPR Companies - Best DNA Editors**](https://media.market.us/top-10-crispr-companies/) | media.market.us | | 6/27/2024 | [**Genome Editing Technologies Market Report 2024-2034 - Emerging Economies Projected ...**](https://finance.yahoo.com/news/genome-editing-technologies-market-report-112000946.html) | [[Yahoo Finance]] | ## Topic Overview (Some LLM-derived content — please confirm with above primary sources) ### Key Players - **Metagenomi**: A company specializing in advanced gene editing technologies, including Adenine Base Editors, aimed at developing curative therapeutics. - **Metagenomi, Inc.**: A biotechnology company focused on developing gene editing tools, including adenine base editors and programmable nucleases, for therapeutic applications. - **CRISPR-Cas9**: A leading genome editing tool that allows for precise modifications to DNA, widely used in gene therapy and clinical trials. - **Editas Medicine**: A leading company in genome editing, specializing in CRISPR technology to develop therapies for genetic disorders. - **Exsilio Therapeutics**: A genome editing startup led by Tal Zaks, focusing on advancing genome editing technologies with significant funding. - **Editas Medicine, Inc.**: A leader in CRISPR technology, currently developing gene editing therapies and collaborating with Genevant Sciences to create in vivo gene editing medicines. - **ToolGen, Inc.**: A leader in genome editing technology, known for its CRISPR RNP technology and involved in patent litigation to protect its innovations. - **Tessera Therapeutics**: Focused on developing in vivo genome editing technologies, including RNA gene writer platforms. - **Scribe Therapeutics**: A company focused on developing advanced genome and epigenome editing tools for safer genetic therapies. - **Integrated DNA Technologies (IDT)**: A company enhancing CRISPR genome editing solutions through partnerships for off-target analysis. - **Qi Biodesign**: A biotechnology firm specializing in next-generation genome editing technologies, recently raised $75 million in Series A funding. - **Calzyme**: A Lithuania-based company utilizing diverse Cas9 orthologs and novel nucleases for gene editing applications. - **HuidaGene Therapeutics**: A biotechnology company focusing on gene editing tools and delivery vectors, recently appointed Dr. TJ Cradick as Chief Technology Officer to enhance their capabilities. - **Hangzhou Qihan Biotech Co., Ltd.**: A biotechnology company focused on genome editing technologies, particularly using CRISPR-Cas9 for livestock health and organ transplantation. - **Abbott Laboratories**: A key player in the CRISPR market, focusing on gene editing applications and personalized medicine. - **Donald Danforth Plant Science Center**: Research institution that developed TATSI, a new genome editing technology aimed at enhancing agricultural sustainability. - **Michigan State University**: Researchers who developed CRISPR-based genome editing methods in Nile grass rats, contributing to preclinical research advancements. - **CRISPR Therapeutics**: A biotechnology company focused on developing transformative gene-based medicines for serious diseases using CRISPR/Cas9 technology. - **Genomics plc**: A company focused on genomic research and applications in healthcare, recently appointed David Thornton as President to enhance operations. ### Partnerships and Collaborations - **Editas Medicine and Genevant Sciences**: Entered a collaboration to develop in vivo gene editing medicines, utilizing Editas' CRISPR technology and Genevant's lipid nanoparticle technology. - **Integrated DNA Technologies and SeQure Dx**: Partnering to enhance CRISPR genome editing solutions with advanced off-target analysis capabilities. - **Epic and GeneDx**: Integrating rapid whole genome sequencing technology into Epic's EHR system for improved genomic insights. - **YolTech and KACTUS**: Partnered to advance the commercialization of YolCas12TM, a proprietary DNA editing technology. - **HuidaGene Therapeutics and Dr. TJ Cradick**: Appointment of Dr. Cradick aims to enhance the development of gene editing tools and delivery vectors. - **Agilent Technologies and BIOVECTRA**: Acquisition aimed at enhancing capabilities in genome editing and biotechnology. - **SOHM, Inc. and an undisclosed partner**: Formed a collaboration to develop microfluidic-based gene editing technology for CAR-T cell therapies. - **Eli Lilly and Genetic Leap**: Collaborating to develop genetic medicine therapeutics using RNA-targeted AI technology. - **PatientsLikeMe and Genome Medical**: Partnering to provide genetics-driven healthcare solutions for personalized insights and care pathways. - **Telesis Bio and Beckman Coulter Life Sciences**: Collaborating to develop scalable biofoundries for on-premise DNA synthesis. - **Form Bio and PacBio**: Launched an AAV Working Group to develop standardized practices and tools for the AAV industry, enhancing collaboration in gene therapy research. - **Scribe Therapeutics and Prevail Therapeutics**: Collaborating to develop in vivo CRISPR-based therapeutics for neurological diseases, showcasing advancements in genetic medicine. - **Texas A&M Health and BurstIQ**: Collaborating to utilize BurstIQ's LifeGraph platform for genomic data governance. - **Genoks and Velsera**: Partnering to integrate Velsera's Clinical Genomics Workspace into Genoks' cancer diagnostic services. - **Hangzhou Qihan Biotech Co., Ltd.**: Collaborated with academic institutions to research CRISPR-Cas9 technology for combating African Swine Fever Virus. - **Global X Management Company and Bloomberg Media**: Collaborated to produce a report on innovation and disruption across various sectors, including healthcare technology. - **Mount Sinai and various AI initiatives**: Engaging in multiple partnerships to enhance AI integration across healthcare programs. - **Harvard Business School and Blavatnik Family Foundation**: Established the Blavatnik Fellowship to foster life science entrepreneurship among HBS alumni and postdoctoral researchers. ### Innovations, Trends, and Initiatives - **Prime Editing**: A versatile form of CRISPR technology being researched for personalized gene-editing therapies for rare metabolic diseases. - **CRISPR-Cas9 Technology**: Widely used for precise genome editing, with recent advancements including PAM-less editing systems and smaller editing tools like TnpB. - **AI Integration in Genome Editing**: Companies like SOHM, Inc. are forming AI teams to optimize genome editing processes and improve therapeutic delivery systems. - **CRISPR Technology Advancements**: Innovations in CRISPR, TALENs, and base editing are enhancing precision and efficiency in genome editing, driving growth in personalized medicine. - **Adenine Base Editors (ABEs)**: Developed by Metagenomi, showing high targetability and specificity for gene editing applications. - **AI in Genome Editing**: Utilization of AI to enhance the design and efficiency of genome editing tools, including the development of new nucleases. - **Market Growth**: The genome editing market is projected to grow significantly, from $7.99 billion in 2023 to $32.72 billion by 2032, driven by advancements in gene therapy and increasing demand for genetically modified organisms. - **Adenine Base Editor (ABE)**: Metagenomi's ABE shows no detectable translocations in primary T-cells, emphasizing precision in gene editing. - **CRISPR-Cas13 Technology**: Emerging as a promising tool for RNA-targeted therapeutics, allowing temporary manipulation of gene expression. - **CRISPR Technology**: Significant advancements in gene editing technology, with a 60-fold increase in patent filings over the past decade. - **Ethical Guidelines in South Africa**: Recent updates to health research guidelines in South Africa allow for discussions on heritable human genome editing, raising ethical concerns. - **Miniaturized CRISPR Systems**: Advancements in compact CRISPR systems are expected to revolutionize gene therapy by improving delivery efficiency. - **Synthetic Biology Market Growth**: Projected to grow from USD 13.1 billion in 2022 to USD 118.1 billion by 2032, driven by advancements in DNA synthesis and gene editing. - **Regulatory Approvals**: The European Commission's approval of the first CRISPR/Cas9 gene-edited therapy for sickle cell disease marks a significant milestone in the field. - **RNA-targeted Therapies**: Emerging focus on RNA-targeted therapies for treating genetic disorders and enhancing cancer treatment. - **TATSI Technology**: Introduced by the Donald Danforth Plant Science Center, it enhances the efficiency of DNA integration in crops. - **Gene and Cell Therapy Growth**: Significant growth in the gene and cell therapy industry, with over 30 FDA-approved products and treatments. - **Next-Generation Sequencing (NGS) Services**: Expected to grow at a CAGR of 21.25% from 2024 to 2031, driven by advancements in precision medicine. ### Challenges and Concerns - **Ethical Implications of Heritable Genome Editing**: The potential for heritable human genome editing raises significant ethical debates, particularly following controversial cases in the past. - **Ethical Considerations**: The rapid advancement of genome editing raises ethical questions regarding its applications in humans and agriculture. - **Safety and Off-Target Effects**: Concerns regarding the safety of genome editing technologies, including potential off-target effects and long-term integration issues. - **Ethical and Regulatory Challenges**: The rise of genome editing technologies raises ethical concerns regarding genetic modifications and data privacy. - **Technical Limitations**: Challenges related to off-target effects and ensuring precision in gene editing applications. - **Off-Target Effects**: Concerns regarding off-target effects in genome editing necessitate comprehensive analysis to ensure safety and efficacy. - **Ethical Concerns**: Ongoing debates regarding the ethical implications of gene editing, particularly in human germline modifications. - **High Costs and Technical Complexity**: The significant costs and complexities associated with genome editing technologies pose barriers to widespread adoption. - **Risks in Gene Editing**: Metagenomi acknowledges inherent risks and uncertainties in their growth strategy and product development, which could impact business outcomes. - **Regulatory Frameworks**: The need for clear regulatory frameworks to govern genome editing practices is critical, especially in light of recent developments in South Africa. - **Regulatory Hurdles**: Navigating complex regulatory environments for gene editing technologies and therapies. - **Delivery Challenges**: The large size of traditional genome editing proteins like Cas9 and Cas12a complicates their delivery into cells. - **Ethical and Regulatory Issues**: The Bioethics Advisory Committee of Singapore published a consultation paper addressing the ethical implications of Human Nuclear Genome Editing (HNGE). - **Patent Infringement Issues**: ToolGen's lawsuit against Vertex Pharmaceuticals highlights ongoing disputes over intellectual property rights in genome editing technologies. - **Data Security and Privacy**: Concerns about the security and potential re-identification of de-identified patient data in genomic research. - **Data Security and Skilled Personnel Shortage**: Challenges in the genomics market include data security issues and a shortage of skilled professionals. - **High Costs of Therapies**: Cell and gene therapies can range from $400,000 to $2 million per dose, posing accessibility issues. - **Access to Innovations**: Concerns about equitable access to advancements in biotechnology and healthcare technology, particularly in personalized medicine. ## Related Topics [[Gene Editing]]; [[Genomics]]